Page last updated: 2024-08-17

chlorisondamine and Atherosclerotic Parkinsonism

chlorisondamine has been researched along with Atherosclerotic Parkinsonism in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abin-Carriquiry, JA; Costa, G; Dajas, F1

Other Studies

1 other study(ies) available for chlorisondamine and Atherosclerotic Parkinsonism

ArticleYear
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
    Brain research, 2001, Jan-12, Volume: 888, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra

2001